Cas-regulation-targeting chimera enables selective and tunable control of CRISPR/Cas12a
Nucleic Acids Research · 17.07.2026 · 54 (14)
DOI: 10.1093/nar/gkag765 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 04.08.2026. Verfasst von Yueyuan Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing Research Center for Pharmaceutical Engineering, College of Pharmacy, Chongqing Medical University, Chongqing 400016, P.R. China. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, CRISPR-Associated Proteins, Endodeoxyribonucleases, Bacterial Proteins. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing, Chongqing Talents: Exceptional Young Talents Project, China.
Abstract (Originalsprache)
Selective and tunable regulation of clustered regularly interspaced short palindromic repeats (CRISPR)/Cas12a activity enables on-demand control, yet current strategies remain hindered by nonspecific regulation and limited tunability. Inspired by proximity effect, we present a Cas-regulation-targeting chimera (CasTAC) strategy that employs CRISPR RNA (crRNA) as a proximity mediator to carry phosphorothioate regulators to interfere with catalytic or recognition domains of Cas12a and consequently suppress its activity. This crRNA-induced proximity approach can effectively eliminate nonspecific interaction between phosphorothioate regulators and proteins within complex multi-enzyme systems, thereby enabling selective control over CRISPR/Cas12a activity. Furthermore, CRISPR/Cas12a activity can be finely tuned to different inhibitory levels by varying the number of phosphorothioate regulators. The CasTAC strategy also improves nuclease resistance and single-nucleotide discrimination, offering potential advances in the sensitivity of molecular diagnostics and the accuracy of gene editing. Notably, the CasTAC balances the kinetics of nucleic acid amplification and CRISPR cleavage, facilitating efficient product accumulation and resolving compatibility issues in one-pot assays. As a proof of concept, we develop a one-pot, one-step recombinase polymerase amplification–CasTAC assay that achieves over 1000-fold higher detection sensitivity than the conventional one-pot recombinase polymerase amplification−CRISPR/Cas12a assay. The CasTAC strategy provides a versatile framework for fine–tuning Cas activity and advances CRISPR technology toward refined and context-adaptable functionality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Chongqing Research Center for Pharmaceutical Engineering, College of Pharmacy, Chongqing Medical University, Chongqing 400016, P.R. China.
- Key Laboratory of Luminescence Analysis and Molecular Sensing (Southwest University), Ministry of Education, College of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, P.R. China.
- Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
- Chongqing Talents: Exceptional Young Talents Project, China
Zitieren
APA
Li, Y., Han, P., Yuan, R., Bai, L., & Qing, M. (2026). Cas-regulation-targeting chimera enables selective and tunable control of CRISPR/Cas12a. Nucleic Acids Research, 54(14). https://doi.org/10.1093/nar/gkag765
Vancouver
Li Y, Han P, Yuan R, Bai L, Qing M. Cas-regulation-targeting chimera enables selective and tunable control of CRISPR/Cas12a. Nucleic Acids Research. 2026;54(14). doi:10.1093/nar/gkag765
BibTeX
@article{Li2026,
author = {Li, Yueyuan and Han, Ping and Yuan, Ruo and Bai, Lijuan and Qing, Min},
title = {Cas-regulation-targeting chimera enables selective and tunable control of CRISPR/Cas12a},
journal = {Nucleic Acids Research},
year = {2026},
volume = {54},
number = {14},
doi = {10.1093/nar/gkag765}
}
EUVIMED